Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more
Joinn Laboratories(China)Co (603127) - Net Assets
Latest net assets as of September 2025: CN¥8.12 Billion CNY
Based on the latest financial reports, Joinn Laboratories(China)Co (603127) has net assets worth CN¥8.12 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.53 Billion) and total liabilities (CN¥1.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.12 Billion |
| % of Total Assets | 85.19% |
| Annual Growth Rate | 44.28% |
| 5-Year Change | 559.98% |
| 10-Year Change | 3777.69% |
| Growth Volatility | 128.63 |
Joinn Laboratories(China)Co - Net Assets Trend (2012–2024)
This chart illustrates how Joinn Laboratories(China)Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Joinn Laboratories(China)Co (2012–2024)
The table below shows the annual net assets of Joinn Laboratories(China)Co from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.08 Billion | -2.44% |
| 2023-12-31 | CN¥8.28 Billion | +1.10% |
| 2022-12-31 | CN¥8.19 Billion | +14.65% |
| 2021-12-31 | CN¥7.14 Billion | +483.62% |
| 2020-12-31 | CN¥1.22 Billion | +47.98% |
| 2019-12-31 | CN¥827.26 Million | +26.97% |
| 2018-12-31 | CN¥651.52 Million | +16.80% |
| 2017-12-31 | CN¥557.79 Million | +114.38% |
| 2016-12-31 | CN¥260.18 Million | +24.88% |
| 2015-12-31 | CN¥208.35 Million | +30.98% |
| 2014-12-31 | CN¥159.07 Million | +30.51% |
| 2013-12-31 | CN¥121.89 Million | +22.78% |
| 2012-12-31 | CN¥99.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Joinn Laboratories(China)Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 211791855297.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.09 Billion | 25.93% |
| Common Stock | CN¥749.48 Million | 9.28% |
| Other Components | CN¥5.23 Billion | 64.79% |
| Total Equity | CN¥8.08 Billion | 100.00% |
Joinn Laboratories(China)Co Competitors by Market Cap
The table below lists competitors of Joinn Laboratories(China)Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Webull Corp
NASDAQ:BULL
|
$1.87 Billion |
|
Nordic Semiconductor ASA
PINK:NRSDY
|
$1.87 Billion |
|
Jiangsu Goodwe Power Supply Technology Co Ltd
SHG:688390
|
$1.87 Billion |
|
Hindustan Copper Limited
NSE:HINDCOPPER
|
$1.87 Billion |
|
CTP N.V
PINK:CTPVF
|
$1.87 Billion |
|
Hang Lung Properties Limited
F:AOP
|
$1.87 Billion |
|
China Merchants Port Holdings Company Limited
PINK:CMHHF
|
$1.87 Billion |
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
$1.87 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Joinn Laboratories(China)Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,279,315,724 to 8,078,818,586, a change of -200,497,138 (-2.4%).
- Net income of 74,075,389 contributed positively to equity growth.
- Dividend payments of 119,633,363 reduced retained earnings.
- Share repurchases of 107,861,428 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥74.08 Million | +0.92% |
| Dividends Paid | CN¥119.63 Million | -1.48% |
| Share Repurchases | CN¥107.86 Million | -1.34% |
| Other Changes | CN¥-47.08 Million | -0.58% |
| Total Change | CN¥- | -2.42% |
Book Value vs Market Value Analysis
This analysis compares Joinn Laboratories(China)Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 147.89x to 2.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.22 | CN¥32.41 | x |
| 2013-12-31 | CN¥0.26 | CN¥32.41 | x |
| 2014-12-31 | CN¥0.34 | CN¥32.41 | x |
| 2015-12-31 | CN¥0.45 | CN¥32.41 | x |
| 2016-12-31 | CN¥0.56 | CN¥32.41 | x |
| 2017-12-31 | CN¥1.08 | CN¥32.41 | x |
| 2018-12-31 | CN¥1.05 | CN¥32.41 | x |
| 2019-12-31 | CN¥1.34 | CN¥32.41 | x |
| 2020-12-31 | CN¥1.97 | CN¥32.41 | x |
| 2021-12-31 | CN¥9.80 | CN¥32.41 | x |
| 2022-12-31 | CN¥10.91 | CN¥32.41 | x |
| 2023-12-31 | CN¥11.05 | CN¥32.41 | x |
| 2024-12-31 | CN¥10.91 | CN¥32.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Joinn Laboratories(China)Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.67%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.16x
- Recent ROE (0.92%) is below the historical average (15.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 9.70% | 9.88% | 0.26x | 3.83x | CN¥-301.67K |
| 2013 | 18.34% | 15.50% | 0.38x | 3.13x | CN¥10.13 Million |
| 2014 | 30.87% | 26.51% | 0.41x | 2.85x | CN¥33.12 Million |
| 2015 | 23.64% | 23.80% | 0.43x | 2.32x | CN¥28.37 Million |
| 2016 | 19.89% | 21.38% | 0.40x | 2.30x | CN¥25.71 Million |
| 2017 | 13.71% | 25.37% | 0.32x | 1.69x | CN¥20.70 Million |
| 2018 | 16.63% | 26.50% | 0.36x | 1.75x | CN¥43.21 Million |
| 2019 | 22.60% | 29.21% | 0.45x | 1.72x | CN¥104.12 Million |
| 2020 | 25.72% | 29.28% | 0.51x | 1.72x | CN¥192.52 Million |
| 2021 | 7.81% | 36.76% | 0.18x | 1.20x | CN¥-156.16 Million |
| 2022 | 13.13% | 47.37% | 0.22x | 1.27x | CN¥255.89 Million |
| 2023 | 4.79% | 16.71% | 0.24x | 1.21x | CN¥-430.94 Million |
| 2024 | 0.92% | 3.67% | 0.21x | 1.16x | CN¥-733.81 Million |
Industry Comparison
This section compares Joinn Laboratories(China)Co's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,767,087,259
- Average return on equity (ROE) among peers: 6.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Joinn Laboratories(China)Co (603127) | CN¥8.12 Billion | 9.70% | 0.17x | $1.87 Billion |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |